A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0366-5

Related search